{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:16:34Z","timestamp":1770063394673,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    As neuroendocrine neoplasms (NEN) undergo increasing dedifferentiation, CXC chemokine receptor type 4 (CXCR4) becomes upregulated. Higher levels of CXCR4 are associated with invasive growth, metastasis formation, and poor prognosis. CXCR4 is considered a potential diagnostic biomarker and a promising target for precision therapies \u2014 e.g., endoradiotherapeutic approaches, monoclonal antibodies, or small-molecule inhibitors. A variety of systemic therapies are used to treat metastatic NEN, which may modulate CXCR4 expression and potentially influence the efficacy of future CXCR4-targeted strategies. In the NEN cell lines BON-1, QGP-1, and MS-18, we applied cisplatin, etoposide, streptozotocin, 5-fluorouracil, temozolomide, and everolimus- all systemic agents used in highly proliferative NEN. Following incubation, CXCR4 expression was quantified by qRT-PCR, Western blot, and immunohistochemistry. The functional receptor activity was determined by measuring uptake of the radioligand [68Ga]Pentixafor. Cisplatin induced a significant reduction in CXCR4 mRNA levels in BON-1 and QGP-1 cells (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05) and decreased radioligand uptake in QGP-1 and MS-18. Etoposide, 5-FU, and streptozotocin had no significant impact on CXCR4 expression or uptake activity. Temozolomide and Everolimus markedly diminished both CXCR4 mRNA and protein levels with no significant impact on radioligand uptake. In high-grade NEN cell lines, Cisplatin, Everolimus, and Temozolomide substantially diminish CXCR4 expression, with Cisplatin significantly decreasing CXCR4-targeted radioligand uptake. These findings might have an impact on the optimal therapy sequence and patient selection for future CXCR4-targeted approaches. Further, the decreased CXCR4 expression could represent a new mechanism of action of the established drugs Cisplatin, Temozolomide, and Everolimus.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-37026-8","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:45:34Z","timestamp":1769845534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of neuroendocrine neoplasm-specific systemic treatments on expression and function of CXCR4 in neuroendocrine tumor cells"],"prefix":"10.1038","volume":"16","author":[{"given":"Christof","family":"D\u00e4ubler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura-Sophie","family":"Landwehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Meining","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Michalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Hartrampf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee","family":"Rogoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Weich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"issue":"4","key":"37026_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","volume":"23","author":"S Das","year":"2021","unstructured":"Das, S., Dasari, A. & Epidemiology Incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr. Oncol. Rep. 23 (4), 43 (2021).","journal-title":"Curr. Oncol. Rep."},{"issue":"2","key":"37026_CR2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s12022-014-9313-z","volume":"25","author":"G Rindi","year":"2014","unstructured":"Rindi, G., Petrone, G. & Inzani, F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr. Pathol. 25 (2), 186\u2013192 (2014).","journal-title":"Endocr. Pathol."},{"issue":"10","key":"37026_CR3","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3748\/wjg.v28.i10.1009","volume":"28","author":"JM Fang","year":"2022","unstructured":"Fang, J. M., Li, J. & Shi, J. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. World J. Gastroenterol. 28 (10), 1009\u20131023 (2022).","journal-title":"World J. Gastroenterol."},{"issue":"29","key":"37026_CR4","doi-asserted-by":"publisher","first-page":"27566","DOI":"10.18632\/oncotarget.4491","volume":"6","author":"D Kaemmerer","year":"2015","unstructured":"Kaemmerer, D. et al. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy. Oncotarget 6 (29), 27566\u201327579 (2015).","journal-title":"Oncotarget"},{"key":"37026_CR5","doi-asserted-by":"crossref","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up <\u2009sup>\u2020. Annals of Oncology. 2020;31(7):844\u201360.","DOI":"10.1016\/j.annonc.2020.03.304"},{"issue":"6","key":"37026_CR6","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.7150\/thno.18754","volume":"7","author":"RA Werner","year":"2017","unstructured":"Werner, R. A. et al. Imaging of chemokine receptor 4 expression in neuroendocrine Tumors - a triple tracer comparative approach. Theranostics 7 (6), 1489\u20131498 (2017).","journal-title":"Theranostics"},{"issue":"3","key":"37026_CR7","doi-asserted-by":"publisher","first-page":"e13249","DOI":"10.1111\/jne.13249","volume":"35","author":"H Sorbye","year":"2023","unstructured":"Sorbye, H. et al. European neuroendocrine tumor society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J. Neuroendocrinol. 35 (3), e13249 (2023).","journal-title":"J. Neuroendocrinol."},{"key":"37026_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fendo.2018.00146","volume":"9","author":"S Exner","year":"2018","unstructured":"Exner, S., Prasad, V., Wiedenmann, B. & Gr\u00f6tzinger, C. Octreotide does not inhibit proliferation in five neuroendocrine tumor cell lines. Front. Endocrinol. (Lausanne). 9, 146 (2018).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"37026_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.biocel.2017.12.018","volume":"95","author":"J Teixid\u00f3","year":"2018","unstructured":"Teixid\u00f3, J., Mart\u00ednez-Moreno, M., D\u00edaz-Mart\u00ednez, M. & Sevilla-Movilla, S. The good and bad faces of the CXCR4 chemokine receptor. Int. J. Biochem. Cell Biol. 95, 121\u2013131 (2018).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"37026_CR10","doi-asserted-by":"crossref","unstructured":"Sanchis-Pascual, D. et al. CXCR4: from signaling to clinical applications in neuroendocrine neoplasms. Cancers (Basel) ;16(10). (2024).","DOI":"10.3390\/cancers16101799"},{"issue":"17","key":"37026_CR11","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.2174\/0929867324666170830111531","volume":"26","author":"W Zhou","year":"2019","unstructured":"Zhou, W., Guo, S., Liu, M., Burow, M. E. & Wang, G. Targeting CXCL12\/CXCR4 axis in tumor immunotherapy. Curr. Med. Chem. 26 (17), 3026\u20133041 (2019).","journal-title":"Curr. Med. Chem."},{"issue":"6","key":"37026_CR12","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","volume":"26","author":"B Bockorny","year":"2020","unstructured":"Bockorny, B. et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat. Med. 26 (6), 878\u2013885 (2020).","journal-title":"Nat. Med."},{"issue":"7","key":"37026_CR13","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/RLU.0000000000004674","volume":"48","author":"A Weich","year":"2023","unstructured":"Weich, A. et al. Impact of CXCR4-Directed PET\/CT on staging and proposed oncologic management in patients with digestive system tumors. Clin. Nucl. Med. 48 (7), 586\u2013593 (2023).","journal-title":"Clin. Nucl. Med."},{"issue":"1","key":"37026_CR14","first-page":"35","volume":"201","author":"MA Fath","year":"2024","unstructured":"Fath, M. A. et al. Chemokine receptor CXCR4 radioligand targeted therapy using 177Lutetium-pentixather for pulmonary neuroendocrine cancers. Radiat. Res. 201 (1), 35\u201347 (2024).","journal-title":"Radiat. Res."},{"key":"37026_CR15","doi-asserted-by":"crossref","unstructured":"Weich, A. et al. Wnt\/\u03b2-Catenin signaling regulates CXCR4 expression and [(68)Ga] pentixafor internalization in neuroendocrine tumor cells. Diagnostics (Basel) ;11(2). (2021).","DOI":"10.3390\/diagnostics11020367"},{"key":"37026_CR16","doi-asserted-by":"crossref","unstructured":"Rogoll, D. et al. World first hybrid neuroendocrine cell line sharing properties of NET G3 and dedifferentiated NEC. (2025). [Manuscript submitted for publication].","DOI":"10.1093\/ejendo\/lvaf159"},{"issue":"7","key":"37026_CR17","doi-asserted-by":"publisher","first-page":"e22049","DOI":"10.1371\/journal.pone.0022049","volume":"6","author":"D Rogoll","year":"2011","unstructured":"Rogoll, D., Schauber, J., Mheta, K. K., Stich, A. & Scheppach, W. Differential Cathelicidin expression in duodenal and gastric biopsies from Tanzanian and German patients. PLoS One. 6 (7), e22049 (2011).","journal-title":"PLoS One"},{"issue":"5","key":"37026_CR18","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/ijc.10098","volume":"97","author":"H L\u00fchrs","year":"2002","unstructured":"L\u00fchrs, H. et al. Modulation of HMG-N2 binding to chromatin by butyrate-induced acetylation in human colon adenocarcinoma cells. Int. J. Cancer. 97 (5), 567\u2013573 (2002).","journal-title":"Int. J. Cancer"},{"key":"37026_CR19","unstructured":"GelAnalyzer 23. 1.1 (available at www.gelanalyzer.com) by Istvan Lazar Jr. PaILS, PhD, CSc.\u00a0"},{"issue":"7","key":"37026_CR20","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.18632\/oncotarget.3217","volume":"6","author":"H Zhao","year":"2015","unstructured":"Zhao, H. et al. CXCR4 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget 6 (7), 5022\u20135040 (2015).","journal-title":"Oncotarget"},{"issue":"5","key":"37026_CR21","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/JLB.5BT1219-714R","volume":"109","author":"M Martin","year":"2021","unstructured":"Martin, M. et al. At the bedside: profiling and treating patients with CXCR4-expressing cancers. J. Leukoc. Biol. 109 (5), 953\u2013967 (2021).","journal-title":"J. Leukoc. Biol."},{"key":"37026_CR22","doi-asserted-by":"publisher","unstructured":"Weich, A. et al. CXCR4-Directed PET\/CT in patients with newly diagnosed neuroendocrine carcinomas. Diagnostics (Basel) ;11(4). 605 https:\/\/doi.org\/10.3390\/diagnostics11040605 PMID: 33805264; PMCID: PMC8067200. (2021).","DOI":"10.3390\/diagnostics11040605"},{"issue":"2","key":"37026_CR23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11307-024-01899-w","volume":"26","author":"K Michalski","year":"2024","unstructured":"Michalski, K. et al. Volumetric parameters derived from CXCR4-Directed PET\/CT predict outcome in patients with Gastrointestinal neuroendocrine carcinomas. Mol. Imaging Biol. 26 (2), 344\u2013350 (2024).","journal-title":"Mol. Imaging Biol."},{"issue":"2","key":"37026_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1530\/JME-14-0304","volume":"54","author":"T Vandamme","year":"2015","unstructured":"Vandamme, T. et al. Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1. J. Mol. Endocrinol. 54 (2), 137\u2013147 (2015).","journal-title":"J. Mol. Endocrinol."},{"issue":"14","key":"37026_CR25","doi-asserted-by":"publisher","first-page":"18865","DOI":"10.18632\/oncotarget.7738","volume":"7","author":"L Circelli","year":"2016","unstructured":"Circelli, L. et al. CXCR4\/CXCL12\/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. Oncotarget 7 (14), 18865\u201318875 (2016).","journal-title":"Oncotarget"},{"key":"37026_CR26","doi-asserted-by":"publisher","unstructured":"Takeda, T. et al. HER3\/Akt\/mTOR pathway is a key therapeutic target for the reduction of triple\u2013negative breast cancer metastasis via the Inhibition of CXCR4 expression. Int. J. Mol. Med. ;52(3). 80 https:\/\/doi.org\/10.3892\/ijmm.2023.5283 Epub 2023 Jul 21. PMID: 37477145; PMCID: PMC10555474. (2023).","DOI":"10.3892\/ijmm.2023.5283"},{"issue":"12","key":"37026_CR27","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg, J. R. et al. (177)Lu-Dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22 (12), 1752\u20131763 (2021).","journal-title":"Lancet Oncol."},{"issue":"12","key":"37026_CR28","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1007\/s00259-022-05849-y","volume":"49","author":"AK Buck","year":"2022","unstructured":"Buck, A. K. et al. CXCR4-targeted theranostics in oncology. Eur. J. Nucl. Med. Mol. Imaging. 49 (12), 4133\u20134144 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"51","key":"37026_CR29","doi-asserted-by":"publisher","first-page":"85185","DOI":"10.18632\/oncotarget.13238","volume":"7","author":"S Taromi","year":"2016","unstructured":"Taromi, S. et al. CXCR4 antagonists suppress small cell lung cancer progression. Oncotarget 7 (51), 85185\u201385195 (2016).","journal-title":"Oncotarget"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37026-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37026-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37026-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T09:47:31Z","timestamp":1770025651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37026-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["37026"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-37026-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4339"}}